Novo Nordisk Taps Ascendis For Development Of A Once-Monthly GLP-1 Agonist

Extends TransCon Platform Into Metabolic Diseases

Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.

Once-monthly injections would have a convenience advantage over available once-weekly obesity drugs (Shutterstock)

Who: Novo Nordisk/Ascendis Pharma

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Scrip